Incyte Genomics Inc., known for its databases and research solutions, is acquiring Maxia Pharmaceuticals Inc. and its pipeline of early stage drugs for an amount that could reach $42.3 million. Also Tuesday, the company released its third-quarter earnings and said it was reducing staff by 37 percent and planning to seriously reduce expenses. (BioWorld Today) Read More
